Holen Sie sich die Stockscreener-App
18.14
2.42%
-0.45
Handel nachbörslich:
18.04
-0.10
-0.55%
Schlusskurs vom Vortag:
$18.59
Offen:
$18.71
24-Stunden-Volumen:
1.18M
Relative Volume:
0.99
Marktkapitalisierung:
$567.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-3.2408
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+19.03%
1M Leistung:
+6.21%
6M Leistung:
-44.61%
1J Leistung:
-20.82%
1-Tages-Spanne:
$18.07
$19.23
1-Wochen-Bereich:
$14.43
$19.23
52-Wochen-Spanne:
$14.43
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
18.14 | 581.68M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 9.5%Should You Buy? - MarketBeat
Lenz Therapeutics launch of "Make It Vizzable" with Sarah Jessica Parker as a brand ambassador - marketscreener.com
LENZ Therapeutics and Sarah Jessica Parker announce the launch of 'Make it VIZZable”, the VIZZ consumer campaign - The Manila Times
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign - Yahoo Finance
Sarah Jessica Parker Reveals the Health Issue That Almost Got in the Way of Her Favorite Pastime (Exclusive) - People.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - FinancialContent
Market Review: Will LENZ Therapeutics Inc stock continue upward momentumMarket Trend Review & Weekly Setup with ROI Potential - Bộ Nội Vụ
Shorts Report: How LENZ Therapeutics Inc stock reacts to global recession fearsTake Profit & Fast Exit Strategy with Risk Control - moha.gov.vn
A Look At LENZ Therapeutics (LENZ) Valuation After VIZZ Launch Momentum And New Lunatus Agreement - Yahoo Finance
Published on: 2026-01-12 22:19:01 - Улправда
Aug Momentum: Will LENZ Therapeutics Inc outperform its industry peers2025 Key Lessons & Real-Time Stock Price Movement Reports - baoquankhu1.vn
LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch DataHas The Bull Case Changed? - Yahoo Finance
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
How sustainable is LENZ Therapeutics Inc. stock dividend payoutJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - Улправда
Will LENZ Therapeutics Inc. stock see insider buyingJuly 2025 Short Interest & Accurate Intraday Trading Signals - Улправда
FOMO Trade: Why LENZ Therapeutics Inc. stock is recommended by analysts2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a Potential 245% Upside in the Biotechnology Sector - DirectorsTalk Interviews
LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch - VisionMonday.com
Can LENZ Therapeutics Inc. stock reach $100 price targetJuly 2025 Patterns & Real-Time Buy Signal Alerts - ulpravda.ru
LENZ Therapeutics (NASDAQ:LENZ) Sets New 52-Week LowHere's Why - MarketBeat
Why LENZ Therapeutics Inc. stock is recommended by analystsTrade Risk Assessment & Community Verified Trade Alerts - ulpravda.ru
Why LENZ Therapeutics Inc. stock could outperform in 2025Analyst Upgrade & Risk Controlled Stock Pick Alerts - ulpravda.ru
Why LENZ Therapeutics Inc. stock is popular among millennialsJuly 2025 Selloffs & Daily Oversold Bounce Ideas - Улправда
Analysts Expect Breakeven For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Before Long - Yahoo Finance
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates - The Manila Times
LENZ Therapeutics Reports Strong Initial Sales and Prescription Volume for VIZZ™ after Launch for Presbyopia Treatment - Quiver Quantitative
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Page not foundFactor Thisâ„¢ - FinancialContent
Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East - Yahoo Finance
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ in the Middle East - marketscreener.com
LENZ Therapeutics and Lunatus Ink Exclusive Commercialization Partnership for VIZZ in Middle East - VisionMonday.com
Lenz Therapeutics and Lunatus announce partnership for Vizz(TM) - marketscreener.com
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East - The Manila Times
FDA-approved presbyopia eye drop VIZZ to reach Middle East - Stock Titan
LENZ Therapeutics responds to FDA adverse event report - MSN
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year LowWhat's Next? - MarketBeat
Is LENZ Therapeutics Inc a good long term investmentConsumer Goods Stocks & Free Stay Informed With Forecasts - earlytimes.in
Aug Mood: Why LENZ Therapeutics Inc stock is recommended by analystsQuarterly Profit Summary & Expert Approved Trade Ideas - moha.gov.vn
LENZ Therapeutics (LENZ) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.1%Time to Sell? - MarketBeat
Lenz plunges after adverse event report on eye therapy - MSN
How LENZ Therapeutics Inc. stock compares to industry benchmarksPortfolio Growth Summary & Growth Focused Investment Plans - Улправда
Is LENZ Therapeutics Inc. stock trading near support levels2025 Institutional Moves & Technical Pattern Recognition Alerts - ulpravda.ru
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):